MA53741A - Procédés de traitement de troubles myéloprolifératifs - Google Patents

Procédés de traitement de troubles myéloprolifératifs

Info

Publication number
MA53741A
MA53741A MA053741A MA53741A MA53741A MA 53741 A MA53741 A MA 53741A MA 053741 A MA053741 A MA 053741A MA 53741 A MA53741 A MA 53741A MA 53741 A MA53741 A MA 53741A
Authority
MA
Morocco
Prior art keywords
methods
myeloproliferative disorders
treating myeloproliferative
treating
disorders
Prior art date
Application number
MA053741A
Other languages
English (en)
Inventor
Tymara Berry
John Hood
Catriona Jamieson
Curtis L Scribner
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69950867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53741(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of MA53741A publication Critical patent/MA53741A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MA053741A 2018-09-25 2019-09-24 Procédés de traitement de troubles myéloprolifératifs MA53741A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862736369P 2018-09-25 2018-09-25
US201862783076P 2018-12-20 2018-12-20

Publications (1)

Publication Number Publication Date
MA53741A true MA53741A (fr) 2021-08-04

Family

ID=69950867

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053741A MA53741A (fr) 2018-09-25 2019-09-24 Procédés de traitement de troubles myéloprolifératifs

Country Status (14)

Country Link
US (2) US20220031699A1 (fr)
EP (1) EP3856169A4 (fr)
JP (2) JP2022502492A (fr)
KR (2) KR20210102192A (fr)
CN (1) CN113286584A (fr)
AU (1) AU2019346521B2 (fr)
BR (1) BR112021005518A2 (fr)
CL (1) CL2021000744A1 (fr)
IL (1) IL281736A (fr)
MA (1) MA53741A (fr)
MX (2) MX2021003450A (fr)
MY (1) MY209349A (fr)
SG (1) SG11202103019WA (fr)
WO (1) WO2020068755A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
KR20250134004A (ko) * 2018-09-25 2025-09-09 임팩트 바이오메디신스, 인코포레이티드 골수증식성 장애를 치료하는 방법
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
US20240058336A1 (en) 2020-12-16 2024-02-22 Impact Biomedicines, Inc. Dosing of fedratinib
MX2023009858A (es) 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
WO2023044297A1 (fr) 2021-09-14 2023-03-23 Impact Biomedicines, Inc. Fédratinib pour traiter des troubles myéloprolifératifs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
JP5191391B2 (ja) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
US20090093009A1 (en) * 2007-10-09 2009-04-09 Sum Chan Mass spectrometry method for measuring thiamine in body fluid
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US20130102624A1 (en) * 2011-05-19 2013-04-25 John V. Schloss Early detection of thiamine deficiency
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
WO2015081127A2 (fr) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies pour le traitement de troubles myeloproliferatifs
EP3099677A4 (fr) * 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Dérivés de diaminopyrimidine benzènesulfone et leurs utilisations
CN108348578B (zh) * 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
KR20250134004A (ko) 2018-09-25 2025-09-09 임팩트 바이오메디신스, 인코포레이티드 골수증식성 장애를 치료하는 방법
FR3092581A1 (fr) 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Also Published As

Publication number Publication date
WO2020068755A1 (fr) 2020-04-02
MX2023013844A (es) 2023-12-08
JP2024161416A (ja) 2024-11-19
AU2019346521A1 (en) 2021-05-20
JP2022502492A (ja) 2022-01-11
SG11202103019WA (en) 2021-04-29
EP3856169A1 (fr) 2021-08-04
KR20250164332A (ko) 2025-11-24
MY209349A (en) 2025-07-03
EP3856169A4 (fr) 2022-06-29
AU2019346521B2 (en) 2025-05-08
BR112021005518A2 (pt) 2021-06-29
IL281736A (en) 2021-05-31
MX2021003450A (es) 2021-07-16
US11400092B2 (en) 2022-08-02
US20220133724A1 (en) 2022-05-05
CN113286584A (zh) 2021-08-20
CL2021000744A1 (es) 2021-10-08
KR20210102192A (ko) 2021-08-19
US20220031699A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
MA53741A (fr) Procédés de traitement de troubles myéloprolifératifs
EP3389725A4 (fr) Compositions et méthodes pour le traitement de maladies du système nerveux central
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
EP3448504A4 (fr) Traitement de stimulation cérébrale pour dépression
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3500289A4 (fr) Procédés de traitement de la trachéobronchomalacie
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
EP3331527A4 (fr) Procédés de traitement de troubles du développement à l'aide de pipradrol
EP2970317A4 (fr) Composés pyrimido-diazépinone et procédés de traitement de troubles
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3500267A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs
EP4045037C0 (fr) Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1
EP3433266A4 (fr) Méthodes de traitement de troubles mitochondriaux
EP3833340A4 (fr) Compositions et procédés de traitement de la presbytie
EP3727403A4 (fr) Méthodes intracanalaires de traitement de troubles du sein
EP3481958A4 (fr) Procédés et compositions de traitement de troubles et de maladies impliquant rdh12
EP3313417A4 (fr) Méthodes de traitement de troubles auto-immuns et allo-immuns
EP3801768A4 (fr) Méthodes de traitement de troubles du hyperprolifératifs malins
MA44126A (fr) Méthodes de traitement de maladies et troubles pulmonaires
EP3621434A4 (fr) Méthodes de traitement de troubles neuropsychiatriques
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3826650A4 (fr) Méthodes de traitement de troubles neurologiques
EP3634370A4 (fr) Traitement des troubles cutanés